Clinical trials: Adults With Overweight and Obesity
Diabetes Mellitus, Type 2, Obesity
A Rural OPTIFAST Intervention for Partial Remission of Type 2 Diabetes in Adults With Obesity
As rural Canada is a resource poor health service environment, we propose to test whether an OPTIFAST dietary replacement intervention, without the service intensive behavioural component, can cause partial remission of DMII in…
- Trial name
- NCT04764279
- Testing
- OPTIFAST dietary supplement
- Volunteers
- 30 people
- Sponsor
- Marathon Family Health Team
Obese Adults, Overweight , Obesity
ASSESSMENT OF THE NATURAL HISTORY AND PROGNOSTIC FACTORS OF THERAPEUTIC RESPONSE IN SUB-PHENOTYPES OF PATIENTS WITH OBESITY: THE BOLOBE STUDY
The study is observational and single-center and involves (i) the establishment of a retrospective and prospective data collection, and (ii) the development of prognostic and predictive models of response to obesity therapies…
- Trial name
- BOLOBE (NCT07666425)
- Where
- Italy
- Volunteers
- 10,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Obesity, Overweight
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who…
- Trial name
- NCT07890376
- Testing
- LY4086940
- Where
- 46 sites in United States, Argentina
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Obesity or Overweight
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions
This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of RGT001-075 in adults…
- Trial name
- COMO-1 (NCT06867718)
- Testing
- RGT001-075
- Where
- 35 sites in United States
- Volunteers
- 267 people
- Sponsor
- Regor Pharmaceuticals Inc.
Obesity, Type 2 Diabetes Mellitus (T2DM)
Magnetic Duodeno-Ileal Chile Study
The objective of the MagDI Chile Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side…
- Trial name
- NCT06613724
- Testing
- Magnet System, DI Biofragmentable
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- GT Metabolic Solutions, Inc.
Aerobic Exercise, Strength Training
Home-Based Circuit Training in Overweight/Obese Older Adult Patients With Knee Osteoarthritis and Type 2 Diabetes
Background: Obesity and type 2 diabetes mellitus (T2DM) are considered two of the most prevalent metabolic diseases linked to the onset of knee pain caused by osteoarthritis.
- Conditions
- Aerobic Exercise, Strength Training, Glycemic Control, Blood Pressure
- Trial name
- NCT06309654
- Testing
- 12-week home-based circuit training (HBCT), Standard of care (CONT)
- Where
- Saudi Arabia
- Volunteers
- 70 people
- Sponsor
- Princess Nourah Bint Abdulrahman University
Weight Management
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity
- Trial name
- NCT05813795
- Testing
- Ecnoglutide Low Dosage, Ecnoglutide Medium Dosage, Ecnoglutide High Dosage
- Where
- China
- Volunteers
- 664 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obesity, Metabolic Syndrome
Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)
This study investigates whether the activity of brown adipose tissue (BAT) - a special type of fat that burns energy as heat - can predict how well individuals with obesity respond to semaglutide (Wegovy), a once-weekly…
- Conditions
- Obesity, Metabolic Syndrome, Brown Adipose Tissue
- Trial name
- BAT-Sema (NCT07621640)
- Testing
- Semaglutide (Wegovy®), ¹⁸FDG-PET/CT with cold stimulation, Liver MRI (PDFF + MRE)
- Where
- 2 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Hallym University
Overweight and Obesity, Body Weight
Conjugated Linoleic Acid on Body Weight and Body Fat Mass for 12 Weeks
This study has purpose to assess the effect of conjugated linoleic acid (CLA)-fortified milk powder with nutrition counseling and nutrition module in body weight and body fat mass among overweight and obese adult in Indonesia
- Trial name
- CLAPSProject (NCT04531137)
- Testing
- CLA-fortified milk powder, Nutrition Counseling
- Where
- Indonesia
- Volunteers
- 84 people
- Sponsor
- Universitas Indonesia
Obesity and Overweight
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
- Trial name
- NCT06732245
- Testing
- NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 224 people
- Sponsor
- Biomed Industries, Inc.
Overweight and Obesity
Resistance Training in Adults With Obesity
The purpose of this project is two-fold: (1) to assess if two different resistance training protocols elicit different responses in the acute phase and (2) to assess if the same two different protocols will elicit different…
- Trial name
- NCT05092061
- Testing
- Moderate-repetition resistance training, High-repetition resistance training
- Where
- Norway
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Insulin Resistance, Impaired Glucose Tolerance
Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)
The purpose of this study is to investigate the effects of a fibre mixture added to a high-protein diet on metabolic, gut and brain health.
- Conditions
- Insulin Resistance, Impaired Glucose Tolerance, PreDiabetes, Overweight and Obesity
- Trial name
- DISTAL (NCT05354245)
- Testing
- Fibre supplement (potato-pectin), High-protein diet
- Where
- Netherlands
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Metabolic Syndrome
A Mediterranean Diet-Based Culinary Intervention in Adults With Metabolic Syndrome
Metabolic syndrome is a major public health concern associated with an increased risk of cardiovascular disease, type 2 diabetes, and premature mortality.
- Trial name
- CUINAMET (NCT07702695)
- Testing
- Mediterranean diet-based culinary intervention, Standard nutritional counseling
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Type 1 Diabetes, Obesity
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
- Conditions
- Type 1 Diabetes, Obesity, Overweight
- Trial name
- SURPASS-T1D-1 (NCT06914895)
- Testing
- Tirzepatide
- Where
- 146 sites in United States, Argentina and 10 more
- Volunteers
- 905 people
- Sponsor
- Eli Lilly and Company
Obesity, Type 2 Diabetes
Magnetic Gastro-Ileal or Gastro-Jejunal Diversion Study ("MGI/MGJ Study")
The purpose of this clinical research study is to evaluate the feasibility of the GT Metabolic Solutions Magnet System, GJ Biofragmentable ("MagGJ System") for creation of a side-to-side anastomosis for gastro-ileal or…
- Trial name
- NCT06073457
- Testing
- MagGJ System
- Where
- 4 sites in Canada, Chile and 2 more
- Volunteers
- 35 people
- Sponsor
- GT Metabolic Solutions, Inc.
Type 2 Diabetes Mellitus (T2DM)
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.
- Trial name
- NCT06660173
- Testing
- Maridebart Cafraglutide
- Where
- 96 sites in United States, Austria and 12 more
- Volunteers
- 409 people
- Sponsor
- Amgen
Obesity & Overweight
WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults
This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug…
- Trial name
- NCT07216651
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Closed Loop Medicine
Overweight and Obese Adults, Malnutrition or Risk of Malnutrition
Screening for Malnutrition in Obese Patients
More than half of the Dutch population is overweight or obese, which is associated with an increased risk of COVID-19 and worse outcomes during a COVID-19 infection.
- Trial name
- SCOOP (NCT06626360)
- Where
- 3 sites in Netherlands
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- HAN University of Applied Sciences
Obesity
A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese
The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: how the study medicine, danuglipron, is taken up into the…
- Trial name
- NCT06567327
- Testing
- Danuglipron, Atorvastatin, Rosuvastatin
- Where
- 3 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity & Overweight
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general.
- Trial name
- NCT07728383
- Testing
- Semaglutide 6 mg liquid emulsion formulation, Wegovy® (semaglutide) Tablet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Gila Therapeutics, Inc.